Russian National Congress

Moscow, 15.10.2008, the second consecutive year the pharmaceutical company Krka was the General Sponsor of the Russian National Congress of Cardiology held in Moscow, c 7 and 9 October in the new building of Presidium of Russian Academy Science. The main themes of the Congress this year are new approaches to the treatment of cardiovascular diseases, interventional cardiology, cardiac rehabilitation problems of patients, prevention cardiovascular disease and improving the organization of cardiological services. As in the past year, the company Krka has made significant contributions to the scientific program of work on the main themes of the Congress, organized symposia, which were presented the results of important nationwide survey, conducted with the support of the company Krka. If you would like to know more about J.D. Peterson, then click here. The greatest attention of the Congress drew a symposium, “Atlantic,” by by the President of the All-Russian Scientific Society of Cardiology, academician, RG Oganov. The symposium, which gathered over 900 specialists, were presented results of the first Russian multicenter study with dose escalation of atorvastatin to achieve target cholesterol levels (drug “Atoris,” the company Krka).

Own clinical studies on the drug “Atoris” provide a good evidence base efficacy and safety. The other two of the symposium, organized by Krka “Portrait of ambulatory patients with cardiovascular disease” and “Basic problems and solutions in the treatment of hypertension: a practical aid doctor, “also enjoyed great attention of specialists. As part of the scientific sessions were presented the results of the study “Zeus”: Resistance to aspirin and efficiency clopidogrel (the drug company Krka Zilt) in patients with coronary artery disease after surgical revascularization and outcomes of specific groups with cardiovascular drug Amprilan (ramipril company Krka). A central feature of Exhibition stand company Krka at the Congress was the presentation of a new drug from the group of angiotensin receptor blockers for blood pressure control – “Lorista” (losartan company Krka). In the early summer of 2008 the company plant inKrka Russia to start production of this drug.

Tags: ,


Comments are closed.